The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Plant is part of the company's CAD $30 million capital investment in the site
The appointments will add to the well-diversified experience that currently exists on the PPL board.
Brings 25 years of global operations and supply chain experience to Piramal
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)